• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

HSCT not shown to achieve disease remission in refractory Crohn’s disease

byMilana Bogorodskaya, MDandPriyanka Vedak
December 15, 2015
in Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Hematopoietic stem cell transplant (HSCT) did not significantly achieve disease remission in patients with refractory Crohn’s disease.

2. More patients who underwent HSCT had a non-significant trend towards better quality of life and less active disease on imaging but also had a significantly higher number of infections than those who did not.

Evidence Rating Level: 1 (Excellent)

Study Rundown: This randomized clinical trial looked at the potential benefit of autologous hematopoietic stem cell transplant (HSCT) for the treatment of Crohn’s disease. Only patients who had a poor quality of life, had failed multiple pharmacological treatments, and whose disease was refractory to surgical interventions, were included in the study. The results showed that there was no statistically significant improvement in disease remission between those who underwent HSCT and those who did not. However, there was a non-significant trend towards improved quality of life and no active disease on imaging in the group that underwent HSCT. Adverse side effects, especially infections, were more common in the HSCT group.

The strengths of this study include the randomized nature of the study and the inclusion of objective end points, which reduced the need for a blinded study. Few studies have researched such therapy for Crohn’s disease and although this study did not show statistically significant results, it did show a trend towards improvement for those who underwent HSCT. It is possible that with a larger sample number, the power needed to detect a statistical difference would be met. More research needs to be done to better elucidate the effect of HSCT on Crohn’s disease.

Click to read the study in JAMA

Relevant Reading: Complete remission of Crohn’s disease after high-dose cyclophosphamide and autologous stem cell transplantation.

RELATED REPORTS

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

In-Depth [randomized controlled study]: This multicenter, European, randomized controlled study looked at the benefits of autologous HSCT in 45 patients with refractory Crohn’s disease. Patients were all between 18-50 years of age who had continued refractory disease despite surgical interventions. Patients with active infection, malnutrition, severe comorbidities, or who were pregnant were excluded. Patients were divided into two groups: one who had their HSCT immediately and one who had their HSCT deferred for one year after they underwent successful mobilization of their bone marrow, although a patient with deteriorating clinical status could receive accelerated treatment if in the deferred group, as per the physician’s discretion. Those patients were defined as having failed treatment.

The primary end point was sustainable disease remission 1 year after HSCT. Disease remission was defined as either no treatment in the past 3 months, no mucosal erosion/ulceration, or a CDAI score of <150 which takes into account quality of life and symptoms. Secondary end points were quality of life measures. Results showed no statistical difference in the primary end point between the two randomized groups (8.7% in the immediate HSCT group vs. 4.5%, p = 0.60). However, more patients in the immediate HSCT group (61% vs. 23%, p = 0.01) were able to stop immunosuppressive agents. There was no significant difference between the two groups in the proportion of patients who were free from active disease on imaging (35% vs. 9%, p = 0.54). More patients in the HSCT group (13 vs. 5, p = 0.02) suffered from adverse side effects, most commonly infections.

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autologous stem cell transplantationCrohn's Disease
Previous Post

2 Minute Medicine Rewind December 14, 2015

Next Post

Favorable glioblastoma outcomes with Tumor-Treating Fields plus temozolomide

RelatedReports

Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

August 11, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

June 14, 2022
Next Post
Glioblastoma phenotypes identified on MRI predict molecular behavior

Favorable glioblastoma outcomes with Tumor-Treating Fields plus temozolomide

Corticosteroids improve outcomes in treatment of community-acquired pneumonia

DNR orders may skew hospital mortality rates and rankings

Missed or misinterpreted neuroradiologic findings by trainees at an academic medical center

Missed or misinterpreted neuroradiologic findings by trainees at an academic medical center

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
  • Wellness Check: Spirituality
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options